J&J/Cordis expands Precise stent offerings
This article was originally published in The Gray Sheet
Executive Summary
Rapid exchange versions of Cordis' Precise nitinol carotid stent and Angioguard emboli capture guidewire system debut following FDA approval late last year. Compared with the previously available, over-the-wire versions that debuted last autumn, the Precise RX and Angioguard RX facilitate single-operator use and "more efficient manipulation of the catheter and guidewire," the Johnson & Johnson subsidiary explains. The devices are indicated for carotid artery disease in patients at high risk for adverse events from surgical removal of carotid artery plaque (1"The Gray Sheet" Oct. 2, 2006, In Brief). Cordis' 10,000-patient Sapphire global registry will assess the 30-day major adverse event rate following use of Precise RX and Angioguard RX...